David R. Houck
Geen lopende functies
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Jason Okazaki | M | 48 | 4 jaar | |
John McHutchison | M | 66 | 5 jaar | |
Jeanette Bjorkquist | F | - | 5 jaar | |
William Delaney | M | 52 | 4 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Derek Small | M | 48 | 6 jaar | |
Norbert Riedel | M | 66 |
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | 1 jaar |
Fred W. Lyons | M | - | 13 jaar | |
Mark Auerbach | M | 85 | 10 jaar | |
Thomas Russo | M | 52 | 2 jaar | |
Elizabeth Lacy | F | 59 | 5 jaar | |
Richard Colonno | M | 74 | 4 jaar | |
Pamela Kirby | M | 70 | 11 jaar | |
Michele Anderson | F | - | - | |
Charles Osborne | M | 58 | 12 jaar | |
Christopher J. Pazoles | M | 73 |
Pharmakey LLC
Pharmakey LLC Pharmaceuticals: MajorHealth Technology Pharmakey LLC develops and manufactures pharmaceutical products. It offers pharmaceutical development and due diligence consulting, outsourcing and implementation, regulatory and quality and electronic regulatory publishing services. The company was founded by David R. Houck in January 2008 nd is headquartered in Durham, NC. | 5 jaar |
J. P. Benya | M | 60 | 7 jaar | |
Brian Schwab | M | 59 | 9 jaar | |
Bill Gantz | M | 86 |
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | - |
Samuel Hopkins | M | - | - | |
Walter P. Carney | M | - | - | |
Joseph Talamo | M | 55 | 14 jaar | |
Ashish Khanna | M | 48 |
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | 5 jaar |
Micah Mackison | M | - | - | |
Cassia Cearley | M | 42 |
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | 1 jaar |
Amy Sheehan | F | - | 13 jaar | |
Daryl K. Granner | M | 87 | 13 jaar | |
Luisa Stamm | M | 48 | - |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 27 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- David R. Houck
- Persoonlijk netwerk